Skip to main content
Premium Trial:

Request an Annual Quote

Almac Diagnostics, Epigenomics, Wisconsin Alumni Research Foundation, Enzo Life Sciences

Premium
Almac Diagnostics of Craigavon, UK, has received European Patent No. 1815021, “Transcriptome microarray technology and methods of using the same.” The patent claims arrays containing a transcriptome of a diseased tissue and methods of using the arrays for diagnosis, prognosis, screening, and identification of disease. According to the patent’s abstract, the transcriptome arrays from diseased tissue are useful for diagnosis of a disease by analysis of the genetic profile of a tissue sample specific to a disease state. The genetic profiles are then correlated with data on the effectiveness of specific therapeutic agents. Correlating expression profiles to the effectiveness of therapeutic agents provides a way to screen and select further patients predicted to respond to those therapeutic agents, thereby minimizing needless exposure to ineffective therapy, the abstract states.
 

 
Epigenomics of Berlin has received European Patent No. 1816216, “Oligomer array with PNA and/or oligomers on a surface.” The patent claims an oligomer array with peptide nucleic acid and/or DNA oligomers on a surface, which comprises oligomers of between six and 20 monomers or nucleobases each. The oligomer arrays are used for the detection of cytosine methylations in genomic DNA.
 

 
Wisconsin Alumni Research Foundation of Madison, Wis., has received US Patent No. 7,256,259, “Methods for ligation of molecules to surfaces.” The patent describes a method for a covalent ligation of one or more molecules to one or more surfaces that is site-specific and both rapid and high yielding. The covalent ligation to the surface is based on the reaction of an azide and a phosphinothioester to form an amide bond. The method is particularly well-suited to the immobilization of peptides, proteins, or protein fragments to surfaces, according to the patent’s abstract.
 

 
Enzo Life Sciences of Farmingdale, NY, has received US Patent No. 7,256,299, “Chemiluminescent reagents.” The patent claims labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes, or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe-based assays. They are also applicable to real-time detection processes, the patent’s abstract states.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.